Please login to the form below

Not currently logged in
Email:
Password:

Meda builds marketing muscle

Swedish specialty pharma firm Meda AB has built up its marketing muscle in Western Europe by eating its larger German rival Viatris in a Ä750m deal

Swedish specialty pharma firm Meda AB has built up its marketing muscle in Western Europe by eating its larger German rival Viatris in a Ä750m deal.

Analysts said Viatris' presence in markets such as Germany, France, Spain and the Benelux region would complement Meda's Nordic operations to form a pan-European sales and marketing platform.

In winning the auction to snap up Viatris from private equity firm Advent International, Meda beat a whole host of suitors to the deal: UCB of Belgium and Almirall of Spain were reported to be interested as were Indian generics firms Ranbaxy Laboratories and Wockhardt.

Meda CEO, Anders Lonner, said the combined company would be ìan attractive in-licensing partner with its pan-European organisation in marketing and sales, but also through its capacity in regulatory affairs and product developmentî.

Advent managing director, Ralf Huep, said the excellent fit between the two companies had been an important factor in selecting a buyer for Viatris.

Dominic Hollamby, global head, healthcare group at Rothschild, the investment bank that ran the auction, told the Financial Times: ìIn one bold move Meda has moved into the first division of pan-European drug companies in terms of sales and marketing. They have the geographic representation they needed, there are good synergies and opportunities to sell each other's products.î

While Meda had sales of SKr835m (£61.8m) in the first half of 2005 compared to Viatris's SKr1.875bn (£138m), the Swedish group had a higher operating profit before depreciation and amortisation.

Meda will pay Ä583m for Viatris shares and assume net debt, including pension provisions and similar obligations, of Ä167m.

Viatris' most important therapeutic area is respiratory; the company developed the patented Novolizer device, an innovative multi-dose dry powder inhaler. It also has a strong position in pain and inflammation, a core therapeutic area of Meda.

Meda, which currently has no manufacturing facilities, will be looking to utilise Viatris' production capabilities for inhalation products and tablets.

Shares in Meda jumped 27 per cent to an all-time high of SKr106.50 (£1.68) on the news.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics